Moderna

MRNA

Market cap $10.2B

Moderna, Inc. ( MRNA ) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Stéphane Bancel - CEO & Director Stephen Hoge - President Jerh Collins - Chief Technical Operations & Quality Officer James Mock - Chief Financial Officer Jacqueline Miller - Chief Medical Officer Darin Edwards Raffael Nachbagauer Christine Shaw Kyle Holen Michelle Brown Rose Loughlin - Executive Vice President of Research Lavina Talukdar - Senior VP & Head of Investor Relations Rituparna Das Jeff Savard Craig Kennedy Jamie Collins Suzanne Tracy Wenhao Liu Andrew Semmes Amanda Sorrento Nathan Sauveur John Ward Daniel Kulp Kristine McKinney Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Myles Minter - William Blair & Company L.L.C., Research Division Elizabeth Webster - Goldman Sachs Group, Inc., Research Division Lili Nsongo - Leerink Partners LLC, Research Division Alexandria Hammond - Wolfe Research, LLC Conversation Stéphane Bancel CEO & Director Good morning, good afternoon.

Moderna said on Thursday it secured a five-year loan of $1.5 billion from Ares Management , as it targets up to 10% revenue growth next year.

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028 CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced it has closed a five-year term loan facility for up to $1.5 billion of capital from Ares Management Credit Funds (Ares), a leading global alternative investment manager, to increase flexibility. The non-dilutive debt financing consists of three tranches over five years, including: A $600 million initial term loan funded at closing A $400 million delayed draw term loan facility (DDTL), available in multiple draws at Moderna's discretion through November 2027 An additional $500 million DDTL, available in multiple draws at Moderna's discretion through November 2028.

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028 Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year on path to targeted cash breakeven in 2028 CAMBRIDGE, MA / ACCESS Newswire / November 20, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced program and financial updates at its Analyst Day event. The updates include mRNA pipeline progress and a three-year plan for strategic growth.

Moderna said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the company's domestic production network.

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs CAMBRIDGE, MA / ACCESS Newswire / November 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced the expansion of its U.S. manufacturing capabilities with the onshoring of Drug Product manufacturing to its existing Moderna Technology Center ("MTC") in Norwood, Massachusetts. Through this strategic onshoring, Moderna will now operate full end-to-end manufacturing for its mRNA medicines in the U.S. This milestone marks a significant step in strengthening Moderna's U.S. manufacturing network, supporting both commercial and clinical supply, and reinforcing the Company's commitment to domestic mRNA production.

CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / November 18, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Piper Sandler's 37th Annual Healthcare Conference, on Tuesday, December 2nd at 11:00am ET A live webcast of each of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. investors.modernatx.com.

Moderna (MRNA) stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return. The company's value has increased by approximately $1.2 billion over the last 5 days, leading to a current market capitalization of around $10 billion.

Initiated stake: 500,000 shares, an estimated $12.91 million increase Post-trade Moderna position: 500,000 shares, valued at $12.91 million Moderna now accounts for 1.23% of Telemark's reportable AUM, which places it outside the fund's top five holdings

The headline numbers for Moderna (MRNA) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.